The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 28, 2011
Filed:
Feb. 18, 2004
Otto Westphal, Montreux, CH;
Josette Westphal, Legal Representative, Montreux, CH;
Alexander Westphal, Legal Representative, Montreux, CH;
Thierry Walli, Clarens-Montreaux, CH;
Reginald Gorczynski, Toronto, CA;
Silke Muller, Schonborn, DE;
Jean-pierre Mach, Lausanne, CH;
Alfred Hartman, Erlenbach, CH;
Wolfgang Bessler, Freiburg, DE;
Petra Hofmann, Regensburg, DE;
Ulrich Zahringer, Borstel, DE;
Christian Alexander, Borstel, DE;
Ulrich Vor Dem Esche, Freiburg, DE;
Artur J. Ulmer, Borstel, DE;
Antonio Verdini, Castrocarro Terme, IT;
Otto Westphal, Montreux, CH;
Josette Westphal, legal representative, Montreux, CH;
Alexander Westphal, legal representative, Montreux, CH;
Thierry Walli, Clarens-Montreaux, CH;
Reginald Gorczynski, Toronto, CA;
Silke Muller, Schonborn, DE;
Jean-Pierre Mach, Lausanne, CH;
Alfred Hartman, Erlenbach, CH;
Wolfgang Bessler, Freiburg, DE;
Petra Hofmann, Regensburg, DE;
Ulrich Zahringer, Borstel, DE;
Christian Alexander, Borstel, DE;
Ulrich vor dem Esche, Freiburg, DE;
Artur J. Ulmer, Borstel, DE;
Antonio Verdini, Castrocarro Terme, IT;
Other;
Abstract
The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the γ-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.